SMMT today
$15.68-$0.96 (-5.77%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourSymmetric Triangle
1 hourExpanding
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $19.09
Key levels
Resistance$17.86
Resistance$16.35
Support$14.37
Support$12.07
Latest news & SEC filings
EarningsSummit Therapeutics Posts Q3 2026 Financials
EarningsSummit Therapeutics posts Q3 adjusted loss of $0.20 per share, topping $0.28 consensus
SEC FilingSummit Therapeutics Inc. filed a report on a major company event (Form 8-K)
All SMMT news →About Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company that develops cancer medicines. Its main candidate, ivonescimab, is a bispecific antibody intended to block two biological pathways, and it is being tested in lung and colorectal tumors. The company licenses rights to develop and sell this drug across the Americas, Europe, Japan, the Middle East, and Africa.
Based on the company's 10-K filed Feb 23, 2026.
Nasdaq · Healthcare
Summit Therapeutics Inc. (SMMT)
What Is the Price Target for SMMT?
SEPT Low Target
$11.90
SEPT Mid Target
$23.00
SEPT High Target
$43.00
Analyst Consensus
$23.00
Is SMMT a Buy or Sell Right Now?
Thesis
- •Revenue growing -61.0% YoY with UNKNOWN trend — consistent growth.
- •SEC filings signal active product innovation — 2 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SMMT.
Start Free Trial →Is SMMT Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$17.68
12
Moat Score
NONE
1/9
Piotroski Score
75.3
Altman Z-Score
What Is Smart Money Doing with SMMT?
Insider Signal
BUYING
5 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Anand Bhaskar | officer | Buy | 100,000 | - | Oct 8, 2026 |
| DUGGAN ROBERT W | director officer 10% owner | Buy | 3,810,000 | $50.0M | Jun 12, 2026 |
| Zanganeh Mahkam | director officer 10% owner | Buy | 3,810,000 | $50.0M | Jun 12, 2026 |
| DUGGAN ROBERT W | director officer 10% owner | Buy | 100,000 | $1.5M | Jun 4, 2026 |
| Soni Manmeet Singh | director officer | Buy | 25,000 | $362K | Jun 4, 2026 |
| Zanganeh Mahkam | director officer 10% owner | Buy | 100,000 | $1.5M | Jun 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SMMT Growth Story
Revenue YoY
-61.0%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-364.52%
FCF Growth YoY
-127.5%
Revenue Trend
UNKNOWN
Dark Pool Trades for SMMT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SMMT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:29:54 | $15.72 | 1,000 | $$16K | BUY |
| 15:29:49 | $15.70 | 1,000 | $$16K | BUY |
| 15:29:41 | $15.70 | 5,000 | $$79K | BUY |
| 15:29:25 | $15.67 | 4,900 | $$77K | SELL |
| 15:27:33 | $15.70 | 2,859 | $$45K | BUY |
5 dark pool trades shown · $$232K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for SMMT
PREVIEWSEPT Investing provides real-time options flow tracking for SMMT, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $14.5 | Nov 20 | 8 | $$15.0K | 176 | BLOCK |
| PUT | $15 | Nov 20 | 8 | $$135 | 1 | SWEEP |
| PUT | $15 | Nov 20 | 8 | $$1755 | 13 | SWEEP |
| PUT | $16 | Nov 20 | 8 | $$205 | 1 | SWEEP |
| PUT | $16 | Nov 27 | 15 | $$246 | 1 | SWEEP |
5 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Summit Therapeutics Inc. (SMMT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SMMT — frequently asked questions
What is SMMT stock price today?
Summit Therapeutics Inc. (SMMT) is at $15.68, down 5.77% (-$0.96) at the Nov 12, 2026 close.
Why is SMMT stock moving today?
Latest SMMT news — Nov 4, 2026: Summit Therapeutics Posts Q3 2026 Financials · Nov 4, 2026: Summit Therapeutics posts Q3 adjusted loss of $0.20 per share, topping $0.28 consensus
Why did SMMT stock move on Oct 19, 2026?
Summit Therapeutics shares rose 4.50% to close at $15.57 after the company announced the start of a global Phase II trial of ivonescimab in kidney cancer, with enrollment sites now open for the mid-stage, multi-country study. The trial will evaluate ivonescimab alone or in combination with cadonilimab or ipilimumab in patients with metastatic renal cancer who have received no prior therapy.
What is the SMMT price target?
The average analyst price target for SMMT is $23.00, ranging from $12 to $43, based on 11 analysts. Latest: Citi maintains on Oct 26, 2026.
What do analysts rate SMMT?
Analyst ratings for SMMT: 4 Buy, 9 Hold, 1 Sell — consensus Hold.
Did SMMT beat earnings?
SMMT last reported on Nov 4, 2026: EPS -$0.20 vs -$0.28 expected — a beat of 28.6%.
Does SMMT pay a dividend?
SMMT does not currently pay a dividend.
What are SMMT support and resistance levels?
Support: $14.37, $12.07. Resistance: $16.35, $17.86, $19.09.
What are insiders doing with SMMT?
Insider activity: BUYING, 5 buys and 0 sells in the last 90 days.
What is the latest news on SMMT?
Nov 4, 2026: Summit Therapeutics Posts Q3 2026 Financials · Nov 4, 2026: Summit Therapeutics posts Q3 adjusted loss of $0.20 per share, topping $0.28 consensus · Nov 4, 2026: Summit Therapeutics Inc. filed a report on a major company event (Form 8-K)